<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655340</url>
  </required_header>
  <id_info>
    <org_study_id>Sobi.Alprolix-001</org_study_id>
    <nct_id>NCT03655340</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France</brief_title>
  <acronym>B-SURE</acronym>
  <official_title>A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose
      of this non-interventional study is to describe the real-world usage and effectiveness of
      Alprolix in the on-demand and prophylactic treatment of haemophilia B.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annualised bleeding rate (ABR) (prophylactic treatment)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualised injection frequency (prophylactic treatment)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualised factor consumption (International Unit [IU]) (prophylactic treatment)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of factor Product used to treat a bleed (on-demand treatment)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of injections to treat a bleed (on-demand treatment)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by diary</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">91</enrollment>
  <condition>Haemophilia B</condition>
  <arm_group>
    <arm_group_label>Prophylactic patients</arm_group_label>
    <description>Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On demand patients</arm_group_label>
    <description>Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprolix</intervention_name>
    <description>Extended half-life factor IX product</description>
    <arm_group_label>On demand patients</arm_group_label>
    <arm_group_label>Prophylactic patients</arm_group_label>
    <other_name>Eftrenonacog alfa, rFIXFc</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible patients who present for a routine Clinical visit will be asked to participate
        in the study by the treating physician at participating haemophilia treatment centres in
        France.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of haemophilia B and been treated previously with factor IX Product

          -  Have started Alprolix treatment prior to enrolment visit, or at enrolment prescribed
             treatment with Alprolix, regardless of participation in the study

          -  Signed and dated informed consent provided by the patient, or the patient's legally
             acceptable representative for patients under the legal age, before any study-related
             activities are undertaken. Assent should be obtained from paediatric patients
             according to local regulations

        Exclusion Criteria:

          -  Participation in an investigational medicinal product trial at enrolment visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Santagostino, MD</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Orphan Biovitrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Bordeau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>La Réunion</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum research site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum research site</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum research site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum research site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Coagulation Disorder</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Coagulation Protein Disorder</keyword>
  <keyword>Hemorrhagic Disorder</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

